Both are still in trials but 10 months with chemotherapy versus 2.4 months could bring the drug to the front view of the public, as has been done in the past with activists groups pushing for approval of other drugs. Both are different with treatment plans and the drugs would be limited to the...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
12-04-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, Cancer, clinical trials, Prostate Cancer, PSA, R and D, antigen, testosterone
Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-25-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
The post is a summary of how things look today and under related reading I have included some past posts that may offer a few more details on how the shift it taking place today. Things are also happening and humming as well in China and you can search and find some recent relative posts here as...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-20-2008
Filed under:
Filed under: Pharma/FDA News, My Commentaries, healthcare, Pharma, clinical trials, R and D, India, Economics, Mayo Clinic, Outsourcing, Employment, China pharma
The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-02-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost...
I am guessing this stands to be topic for all in the Pharma business to keep an eye on. There are those in the Indian government too with reservations. The whole idea here is to save money over what the same might cost in the US, as reported earlier, 1/5 is the cost for R and D, thus this...